e-learning
resources
Virtual 2020
Pre-Congress Content
Molecular alterations and immunology in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Role of phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) in non-small cell lung cancer (NSCLC)
P. Tausche (Erlangen, Germany), D. Trufa (Erlangen, Germany), C. Geppert (Erlangen, Germany), R. Rieker (Erlangen, Germany), H. Sirbu (Erlangen, Germany), S. Neurath-Finotto (Erlangen, Germany)
Source:
Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Session:
Molecular alterations and immunology in lung cancer
Session type:
E-poster session
Number:
1643
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Tausche (Erlangen, Germany), D. Trufa (Erlangen, Germany), C. Geppert (Erlangen, Germany), R. Rieker (Erlangen, Germany), H. Sirbu (Erlangen, Germany), S. Neurath-Finotto (Erlangen, Germany). Late Breaking Abstract - Role of phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) in non-small cell lung cancer (NSCLC). 1643
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Definition and history of sarcoidosis
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
The Role of Signal Transducer and Activator of Transcription protein 1 (STAT1) in a murine model of lung adenocarcinoma (ADC)
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017
Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
LSC - 2017 - Proteasomal Activator 200 (PA200) Regulates Cellular Proliferation: A Putative Role For IPF And Lung Cancer Pathogenesis
Source: International Congress 2017 – New insights into pathogenesis of lung disease
Year: 2017
Expression of the ILK-PINCH-PARVIN (IPP) complex and its binding partner Rsu-1 in human non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Late Breaking Abstract - Induction of the transcriptional repressor B lymphocytes-induced maturation protein-1 (Blimp-1) in lung cancer
Source: Virtual Congress 2020 – Biological aspects of lung cancer
Year: 2020
Hypoxia Promotes Human NSCLC Cell Line A549 Motility and EMT Through Extracellular HSP90a
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
Late Breaking Abstract - Anaplastic Lymphoma Kinase inhibition as an effective treatment strategy against the enhanced lung carcinogenesis and cancer angiogenesis related to decreased PTPRZ1 expression
Source: Virtual Congress 2020 – Biological aspects of lung cancer
Year: 2020
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
A role for cAMP-responsive element binding protein in lung adenocarcinoma
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
LATE-BREAKING ABSTRACT: Early relapse of non-small cell lung cancer (NSCLC) found after CNS-symptoms
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Translocation of beta-catenin into cytoplasm during TGFbeta-induced EMT is negatively regulated by phosphorylation of the PTEN C-terminus in lung cancers
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer
Source: Annual Congress 2003 - Lung cancer biology
Year: 2003
The impact of ß-blockers in non–small cell lung cancer patients treated with Epidermal Growth Factor Receptor Kinase Inhibitors, Taiwan NHIRD database study.
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept